Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Zhen Yang has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    TRIM25 Promotes Hepatocellular Carcinoma Bone Metastasis by Stabilizing SMAD3-VDR Complex via SMURF2 Degradation

    by Zhen Yang, Ruipeng Dong, Liming Yao, Nanfeng Meng, Luan Li, Yanlai Sun, Kaiming Leng, Guangjun Shi

    Bone metastasis is a lethal complication of hepatocellular carcinoma (HCC) characterized by severe osteolytic lesions, yet the underlying mechanisms driving osteoclast hyperactivation remain poorly understood. Using quantitative proteomic profiling of clinical cohorts, we identified the E3 ubiquitin ligase TRIM25 as being significantly upregulated specifically in HCC patients with bone metastasis. Elevated TRIM25 expression strongly correlates with poor clinical outcomes, serving as a powerful prognostic indicator. In vivo and in vitro models demonstrated that TRIM25 overexpression significantly accelerates bone colonization and exacerbates osteolytic bone destruction. This aggressive phenotype is driven by the massive paracrine secretion of RANKL from HCC, which profoundly hyperactivates osteoclastogenesis. Mechanistically, we elucidated a dual-ubiquitination regulatory cascade: TRIM25 directly binds to another E3 ligase, SMURF2, catalyzing its K48-linked poly-ubiquitination and subsequent proteasomal degradation. The destruction of SMURF2 acts as an upstream de-repressor that stabilizes SMAD3, facilitating its functional assembly with the Vitamin D Receptor (VDR). This stabilized SMAD3-VDR complex then synergistically transactivates the RANKL promoter, driving robust RANKL expression independent of the canonical TGF-β pathway. Collectively, our study uncovers a previously unrecognized TRIM25-SMURF2-SMAD3/VDR-RANKL signaling axis that orchestrates the tumor-bone microenvironment. Targeting this ubiquitination-driven cascade represents a promising therapeutic strategy to disrupt the vicious cycle of osteolytic bone metastasis in HCC.

  • Open Access

    TTLL12 counteracts BPOZ-2 to stabilize eEF1A1 and promote hepatocarcinogenesis

    by Kaiming Leng, Zhen Yang, Yao Liming, Nanfeng Meng, Yi Xu, Guanqun Liao, Mei Han, Guangjun Shi

    Tubulin tyrosine ligase-like enzyme-12 (TTLL-12), belonging to the TTLL family, holds a crucial position in posttranslational tubulin modifications implicated in cancer development, making it a potential target for anti-tumor therapy. However, the precise mechanisms of TTLL12 in HCC remain inadequately elucidated. In this study, we found markedly elevated expression of TTLL12 in HCC tissues compared to their adjacent normal counterparts, which is strongly linked to an unfavorable prognosis. Functional assays demonstrated that knockdown of TTLL12 significantly suppressed HCC cell proliferation, whereas overexpression of TTLL12 promoted oncogenic behaviors. In vivo models further confirmed that TTLL12 enhances tumor growth, as indicated by larger tumors in TTLL12-overexpressing cells compared to vector controls. Mechanistically, TTLL12 suppressed ubiquitin-proteasome-mediated degradation of eEF1A1 via competing with Bood POZ-containing gene type 2 (BPOZ-2), which typically recruits eEF1A1 to CULLIN (CUL3), and ultimately results in an enhancement of cancer cell proliferation. Our analyses underscore the oncogenic potential of TTLL12 in hepatocarcinogenesis by safeguarding eEF1A1 from BPOZ-2- mediated degradation, introducing a novel therapeutic target for combating HCC.

  • Small bowel neuroendocrine tumors: Unique features and low lethality compared with small bowel adenocarcinoma

    by Zhen Yang, Haibin Xu, Luan Li, Kaiming Leng, Guangjun Shi

    Background and Aim: Population‐based studies comparing clinical characteristics and survival disparities between patients with small bowel adenocarcinoma (SBA) and small bowel neuroendocrine tumors (SBNETs) in the United States are limited. Methods: Data for patients with SBA or SBNETs, obtained from the Surveillance, Epidemiology, and End Results database for the years between 2000 and 2018 were analyzed. Results: Between 2000 and 2018, the age‐adjusted incidence of SBA experienced a marginal increase whereas SBNETs demonstrated a significant increase, emerging as the predominant subtype of small bowel cancer (SBC). Diagnoses peaked at ages 65–69 years for SBA and 60–64 years for SBNETs, with the latter exhibiting a heightened age‐specific incidence and maintaining equilibrium in gender distribution. Clinicopathologic disparities revealed SBA's duodenal predilection, larger tumor size, and advanced stages, contrasting with SBNETs' ileal predilection, early‐stage presentation, and superior outcomes. SBNETs patients underwent surgery more frequently but received less chemotherapy and radiation than SBA patients. Factors intricately correlated with a diagnosis of SBNETs included female gender, White race, advanced age, marital status, recent diagnoses, superior tumor differentiation, smaller size, distal location, and early‐stage presentation. Survival analysis unveiled a remarkable 79% reduction in the mortality risk for SBNETs compared with SBA. Subgroup analysis further confirmed the consistently favorable survival advantages of SBNETs, highlighting the clinical relevance of histological classification in prognostication. Conclusion: Compared with SBA, SBNETs exhibited distinctive clinicopathological features characterized by a higher inclination toward low‐grade and early‐stage manifestations, thereby contributing to superior survival outcomes.


  • Risk of second primary malignancies in survivors of pancreatic neuroendocrine neoplasms from 2000 to 2018

    by Zhen Yang, Lianshuang Liu, Kaiming Leng, Guangjun Shi

    Background and Aim: As a result of improved survival, cancer survivors continue to remain at risk of developing second primary malignancies (SPMs). However, the association between first primary pancreatic neuroendocrine neoplasms (PanNENs) and SPMs has not been thoroughly investigated.Methods: Using the Surveillance, Epidemiology, and End Results‐18 database, patients histologically diagnosed with PanNENs as their first malignancy between 2000 and 2018 were identified. Standardized incidence ratios (SIRs) with 95% confidence intervals (CIs) and excess absolute risks per 10 000 person‐years of SPMs were calculated to estimate the risk of being diagnosed with subsequent cancers compared with the general population.Results: A total of 489 (5.7%) PanNENs survivors developed an SPM during the follow up, with a median latency between first and second cancer diagnoses of 32.0 months. The overall SIR of SPMs was 1.30 (95% CI: 1.19, 1.42) and the excess absolute risk was 35.67 cases per 10 000 person‐years in comparison with the general population. Age 25–64 years at PanNENs diagnosis was associated with statistically higher risks for SPMs of all cancers combined. Latency stratification was significant for elevated SPMs risk between 2–23 and 84+ months after diagnosis. White patients were found to have a significantly increased incidence of SPMs (SIR: 1.23, 95% CI: 1.11, 1.35), mainly owing to the higher risk of stomach, small intestine, pancreas, kidney and renal pelvis, and thyroid cancers.Conclusion: Pancreatic neuroendocrine neoplasms survivors experience a significant increase in the burden of SPMs compared with the reference population. The heightened relative risk calls for careful long‐term scrutiny as part of survivorship care plans.


  • Open Access

    Causes of death among patients with hepatocellular carcinoma in United States from 2000 to 2018

    by Zhen Yang, Kaiming Leng, Guangjun Shi

    Background: The gains in survival outcomes of US patients with hepatocellular carcinoma (HCC) have come at the expense of developing non‐cancer‐related morbidities, such as cardiovascular diseases (CVDs) and infections. However, population‐based data on causes of death (CODs) in patients with HCC are scarce.Methods: A cancer registry database in the United States was used to analyze the CODs among patients with HCC. Death cause distribution and standardized mortality ratios were calculated to quantify the disease‐specific death burden.Results: A total of 40,094 patients with a histological diagnosis of HCC were identified from the SEER‐18 database between 2000 and 2018, of which 30,796 (76.8%) died during the follow‐up period. The majority of these deaths (25,153, 81.7%) occurred within 2 years after diagnosis, 13.2% (4075) occurred within 2–5 years, and 5.1% (1568) occurred after 5 years. All age groups had a lower burden of female deaths than of male deaths during the study period. With respect to CODs, 23,824 (77.4%), 2289 (7.4%), and 4683 (15.2%) were due to HCC, other cancers, and non‐cancer causes, respectively. Non‐cancer‐related deaths were more common among older patients and those with longer latency periods since diagnosis. The major causes of non‐cancer‐related deaths are other infectious and parasitic diseases, including HIV and CVDs.Conclusions: CODs during HCC survivorship varied, and a growing number of survivors tended to die from causes other than HCC, with an increasing latency period since diagnosis. Comprehensive analyses of mortality patterns and temporal trends could underpin strategies to reduce these risks.


  • The asymptotic distribution of robust maximum likelihood estimator with Huber function for the mixed spatial autoregressive model with outliers

    by Zhen Yang, Yihui Luan, Jiming Jiang

    There is a wide range of outliers in spatial data, and these potential outliers will have a great impact on parameter estimation and corresponding statistical inference. Relying on the framework of maximum likelihood estimation (MLE), we investigate the asymptotic distribution of robust ML estimator under the mixed spatial autoregressive models with outliers and compare it with that of the ML estimator. Furthermore, based on the asymptotic theoretical result, we conduct the confidence interval of robust MLE and MLE. Similar to the results of MLE, we construct the second-order-corrected robust confidence interval using the parametric and semi-parametric bootstrap method. Simulation studies using Monte Carlo show that the robust estimator with the Huber loss function is more accurate and outperforms the MLE in most sample settings when data is contaminated by outliers. Then the use of the method is demonstrated in the analysis of the Neighborhood Crimes Data and the Boston Housing Price Data. The results further support the eligibility of the robust method in practical situations.


  • Open Access

    Survival outcomes of combined hepatocellular‐cholangiocarcinoma compared with intrahepatic cholangiocarcinoma: A SEER population‐based cohort study

    by Zhen Yang, Guangjun Shi

    Background: Combined hepatocellular‐cholangiocarcinoma (CHC) is a heterogeneous group of primary liver cancers characterized by the coexistence of both hepatic and biliary cellular contents. The aim of this study was to compare CHC and intrahepatic cholangiocarcinoma (ICC) and investigate the treatment and survival of patients with CHC.Methods: Data on CHC and ICC, including clinicopathological characteristics, treatments, and survival outcomes were extracted from the SEER database between 2004 and 2016. Univariate and multivariate analyses of all data were performed to identify the risk factors associated with survival outcomes. The overall survival (OS) rates of CHC patients who underwent hepatic resection (HR) or liver transplantation (LT) were also assessed before and after propensity score matching.Results: A total of 1066 consecutive patients who had been diagnosed with CHC (n = 286) or ICC (n = 780) were identified. The mean age of the CHC cohort was 60.8±10.7 years old. Among the CHC group, a large proportion of the patients were men and of White ethnicity (73.1% and 71.3%, respectively). The majority of tumors were poorly differentiated (37.8%), while the most common AJCC stage at presentation was stage I (31.4%). Multivariable analysis of all CHC patients revealed that only tumor size, M1 stage, AJCC stage IIIC, AJCC stage IV, surgery, and chemotherapy were significantly associated with OS. The OS was comparable with the ICC in the initial 36 months and better in the subsequent follow‐up after treatment. Surgery was associated with better survival outcomes, whether in the early or advanced stages. Regarding the specific types of surgery, the OS rates were similar in selected patients following HR or LT.Conclusion: In patients with CHC, surgical intervention resulted in better long‐term survival outcomes than nonsurgical treatments. The OS rate of CHC patients compared with that of ICC patients was discriminated before and after a 3‐year follow‐up.


  • Comparison of clinical outcomes between enucleation and regular pancreatectomy in patients with non-functional pancreatic neuroendocrine tumors: a retrospective multicenter and propensity score-matched study

    by Zhen Yang, Hengjun Gao, Jun Lu, Zheyu Niu, Huaqiang Zhu, Yuanyuan Zong, Xie Song, Faji Yang, Xu Zhou

    Objective: There are limited data from retrospective studies on whether therapeutic outcomes after regular pancreatectomy are superior to those after enucleation in patients with small, peripheral and well-differentiated non-functional pancreatic neuroendocrine tumors. This study aimed to compare the short- and long-term outcomes of regular pancreatectomy and enucleation in patients with non-functional pancreatic neuroendocrine tumors. Methods: Between January 2007 and July 2020, 227 patients with non-functional pancreatic neuroendocrine tumors who underwent either enucleation (n = 89) or regular pancreatectomy (n = 138) were included. Perioperative complications, disease-free survival, and overall survival probabilities were compared. Propensity score matching was performed to balance the baseline differences between the two groups. Results: The median follow-up period was 60.76 months in the enucleation group and 43.29 months in the regular pancreatectomy group. In total, 34 paired patients were identified after propensity score matching. The average operative duration in the enucleation group was significantly shorter than that in the regular pancreatectomy group (147.94 ± 42.39 min versus 217.94 ± 74.60 min, P < 0.001), and the estimated blood loss was also significantly lesser (P < 0.001). The matched patients who underwent enucleation displayed a similar overall incidence of postoperative complications (P = 0.765), and a comparable length of hospital stay (11.12 ± 3.90 days versus 9.94 ± 2.62 days, P = 0.084) compared with those who underwent regular pancreatectomy. There were no statistically significant differences between the two groups in disease-free survival and overall survival after propensity score matching. Conclusion: Enucleation in patients with non-functional pancreatic neuroendocrine tumors was associated with shorter operative time, lesser intraoperative bleeding, similar overall morbidity of postoperative complications, and comparable 5-year disease-free survival and overall survival when compared with regular pancreatectomy.